Traffic Lights - Latest Updates

Last updated: 19/05/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
ABATACEPT Red Rheumatoid arthritis

In line with NICE TA 195 and NICE TA 280 and NICE TA715

ABROCITINIB (Cibinqo ®) Grey Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy

Not yet reviewed

ADALIMUMAB Red Moderate rheumatoid arthritis.

In line with NICE TA715

BIMEKIZUMAB (Bimzelx®) Red Moderate to severe plaque psoriasis

In line with NICE TA723

CASIRIVIMAB AND IMDEVIMAB (Ronapreve®) Red For patients hospitalised due to COVID-19
CENOBAMATE (NEW) Red Focal onset seizures in epilepsy
CHLOROPROCAINE HYDROCHLORIDE (Ampres®) Do not prescribe Spinal anesthesia for orthopedic & urology day cases lasting 40 to 60 mins

Reviewed by TAS September 2021

DANTROLENE LIQUID (NEW) Red severe chronic spasticity

Please note this traffic light is for the liquid preparation.

EMPAGLIFLOZIN (NEW) Yellow Chronic heart failure with reduced ejection fraction.

In line with NICE TA773

ETANERCEPT Red Moderate rheumatoid arthritis.

In line with NICE TA715

GLYCOPYRONIUM/BECLOMETASONE/FORMETEROL DPI (Trimbow NEXThaler) Green Maintenance treatment of adults with moderate to severe COPD

Reviewed by the Respiratory Prescribing Group September 2021

HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) (UPDATED) Yellow Adrenal insufficiency in paediatrics
INFLIXIMAB Red Moderate rheumatoid arthritis.

In line with NICE TA715

IXEKIZUMAB (Taltz®) Red Axial spondyloarthritis

In line with NICE TA718

 

MOMETASONE/ OLOPATADINE NASAL SPRAY (Ryaltris ®) Grey Moderate to severe nasal symptoms associated with allergic rhinitis

Not yet reviewed

PEGCETACOPLAN (NEW) Do not prescribe Paroxysmal nocturnal haemoglobinuria (PMH)

Recommended by NICE TA788 but all prescribing is via the national PMH centre

PITOLISANT (NEW) Do not prescribe Excessive daytime sleepiness caused by obstructive sleep apnoea

Not recommended by NICE TA776

PROGESTERONE SC INJECTION (Lubion®) Yellow Patients not absorbing sufficient progesterone from cyclogest or unable to tolerate cyclogest following IVF

Yellow once pregnancy confirmed. Initial treatment before the pregnancy occurs to be provided by secondary care.

QUINIDINE Red KCNT1 gene mutation related Early Infantile Epileptic Encephalopathy

Reviewed by TAS September 2021

RUPATADINE (NEW) Red Urticaria in paediatrics
SECUKINUMAB Red Psoriatic arthritis

In line with NICE TA445

SECUKINUMAB Red Psoriasis

In line with NICE TA350

SECUKINUMAB Red Ankylosing spondylitis.

Use in line with NICE TA407

SECUKINUMAB (Cosentyx®) Red Non-radiographic axial spondyloarthritis

In line with NICE TA719

 

SECUKINUMAB (Cosentyx®) (NEW) Red Treating moderate to severe plaque psoriasis in children and young people

In line with NICE TA734

 

UPADACITINIB (Rinvoq®) (NEW) Red Active psoriatic arthritis after inadequate response to DMARDs

Comments: In line with NICE TA768

Other Updates on this Website

Recent documents from LLR APC and TAS


About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more